Clinical Trial Update: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating sintilimab with GEMOX ± IBI305 (bevacizumab biosimilar) versus GEMOX in advanced intrahepatic cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• GEMOX (gemcitabine + oxaliplatin)
• IBI305 (bevacizumab biosimilar)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN